Market Overview

Cataract Therapeutics | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest drug pipeline analysis report on cataract
therapeutics
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat cataract.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180807005728/en/

Technavio has published a new report on the drug development pipeline for cataract therapeutics, inc ...

Technavio has published a new report on the drug development pipeline for cataract therapeutics, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Cataract: Market overview

Cataract can be defined as a type of disease that arises due to the
clouding of the eye's natural lens, which lies behind iris and pupil.
Cataract can start at any age, and sometimes, it may be present from
birth. It begins when the protein in the eye forms clumps and prevents
the lens from sending clear images to the retina. Companies are focusing
on developing molecules with heat shock proteins, also known as alpha
crystalline, which prevents misfolded proteins from aggregating in the
lens of the eye. For instance, Plex Pharmaceuticals developed a novel
compound, which is an alpha crystalline activator that helps in
maintaining proper refractive index in the lens. This delay prevents the
formation of cataracts, the major cause of blindness in the world.

Cataract therapeutics: Segmentation analysis

This pipeline analysis report segments the cataract therapeutics market
based on therapies employed (monotherapy), RoA (opthalmic and topical),
therapeutic modality (small molecule, monoclonal antibody and protein),
targets (glucocorticoid receptor, alpha-crystallin, beta-L crystallin,
calpain, G8 receptor, nerve growth factor receptor, and protein
aggregation), MoA (glucocorticoid receptor agonist, alpha-crystallin
activator, beta-L crystallin inhibitor, calpain inhibitor, G8 receptor
inhibitor, nerve growth factor receptor agonist, and protein aggregation
inhibitor), geographical segmentation (US and Italy) and recruitment
status (completed and recruiting). It provides an in-depth analysis of
the prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, close to 67% of the molecules that are
being investigated for the treatment of cataract are small molecule.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!